ongo
need
new
adjuv
facilit
develop
vaccin
hiv
tuberculosi
malaria
cancer
amongst
mani
other
unfortun
potent
adjuv
often
associ
toxic
safeti
issu
inulin
plantderiv
polysaccharid
immunolog
activ
nativ
solubl
form
crystallis
stabl
microparticl
delta
inulin
acquir
potent
adjuv
activ
delta
inulin
shown
enhanc
humor
cellular
immun
respons
broad
rang
coadminist
viral
bacteri
parasit
toxin
antigen
inulin
normal
crystallis
larg
heterogen
particl
broad
size
distribut
variabl
solubl
temperatur
ensur
reproduc
delta
inulin
particl
consist
size
distribut
temperatur
solubl
current
good
manufactur
practic
cgmp
process
design
produc
adjuv
cgmp
form
adjuv
prove
success
human
trial
vaccin
season
pandem
influenza
hepat
b
insect
sting
anaphylaxi
enhanc
antibodi
tcell
respons
time
safe
well
toler
adjuv
therebi
repres
novel
human
adjuv
posit
effect
humor
cellular
immun
review
describ
discoveri
develop
adjuv
research
uniqu
mechan
action
inulin
simpl
plantbas
fructan
polysaccharid
compris
famili
linear
polyfructofuranosyl
polym
chain
unbranch
chain
fructos
ring
termin
singl
glucos
fig
inulin
utilis
storag
carbohydr
plant
composita
famili
includ
dahlia
chicori
artichok
onion
garlic
review
inulin
medicin
use
date
back
ancient
time
pedanio
dioscorid
physician
roman
armi
report
benefici
effect
chicori
root
extract
inulin
weight
treatment
stomach
liver
kidney
complaint
inulin
extract
german
scientist
boil
water
extract
inula
helenium
base
inula
sourc
thomson
gave
extract
name
inulin
oral
inulin
benefici
effect
metabol
disord
rediscov
report
diabet
patient
lost
glycosuria
put
diet
gram
inulin
per
day
dietari
inulin
favour
effect
blood
sugar
level
patient
type
diabet
also
reduc
fast
insulin
concentr
triacylglycerol
level
hepat
lipogenesi
inulin
also
shown
reduc
atherosclerot
lesion
apo
edefici
mice
furthermor
short
chain
fatti
acid
includ
butyr
propion
form
inulin
ferment
gut
antiprolif
effect
stimul
apoptosi
colon
cancer
cell
enhanc
express
enzym
includ
histon
deacetylas
involv
detoxif
carcinogen
inulin
ferment
product
gut
also
antiinflammatori
effect
may
help
suppress
autoimmun
diseas
although
inulin
metabolis
gut
flora
inabl
mammal
metabolis
inject
inulin
led
shannon
smith
explor
inulin
use
measur
glomerular
filtrat
gfr
confirm
nontox
inulin
intraven
inject
gram
solubl
inulin
therebi
confirm
inulin
except
safeti
inject
solubl
inulin
subsequ
becam
gold
standard
gfr
measur
intraven
inject
load
dose
mgkg
bodi
weight
follow
infus
maintain
steadi
plasma
level
measur
urinari
inulin
provid
estim
gfr
mani
thousand
patient
safe
gfr
test
includ
pregnant
women
newborn
babi
known
advers
effect
attribut
inulin
mild
osmot
diuresi
earli
day
hospit
made
inulin
formul
patient
receiv
inulin
infus
occasion
develop
transient
hypotens
symptom
found
reflect
complement
activ
independ
known
call
classic
complement
pathway
search
mechan
complement
activ
inulin
led
discoveri
altern
complement
pathway
acp
acp
activ
found
occur
inject
inulin
entir
dissolv
microscop
crystallin
inulin
contamin
respons
acp
activ
henc
found
acp
activ
uniqu
featur
crystallin
solubl
inulin
featur
critic
later
use
vaccin
adjuv
describ
complement
activ
shown
effect
kill
cancer
cell
anim
human
earli
demonstr
anticanc
effect
complement
utilis
complement
activ
staphlococcu
aureu
protein
albeit
major
side
effect
includ
pyrexia
nausea
vomit
signific
cardiopulmonari
toxic
attribut
enterotoxin
b
contamin
format
immun
complex
avoid
problem
use
aureu
complement
activ
altern
approach
cancer
therapi
develop
cooper
et
al
idea
use
inulin
crystal
instead
complement
activ
work
led
discoveri
crystallin
isoform
inulin
given
name
gamma
inulin
distinguish
previous
known
highli
solubl
alpha
beta
inulin
isoform
gamma
inulin
potent
acp
activ
human
plasma
reach
maximum
mice
intraperiton
administr
gamma
inulin
dose
mg
induc
greater
serum
complement
deplet
within
minut
complement
level
return
normal
within
hour
despit
potent
acp
activ
intraperiton
subcutan
inject
gamma
inulin
mice
dose
mg
well
toler
mice
exhibit
advers
effect
intraperiton
administr
gamma
inulin
mice
implant
melanoma
cell
line
prolong
surviv
time
wherea
deplet
complement
factor
mice
abrog
protect
effect
consist
gamma
inulin
antitumour
effect
mediat
acp
activ
gamma
inulin
similarli
induc
tumour
regress
inject
squamou
cell
carcinoma
sheep
effect
enhanc
combin
therapi
cyclophosphamid
intralesion
inject
gamma
inulin
equin
sarcoid
spontan
tumour
dog
similarli
result
tumour
regress
p
cooper
person
commun
gamma
inulin
also
potenti
anticanc
effect
photodynam
therapi
acpdepend
manner
complement
key
compon
innat
immun
system
also
play
import
role
gener
adapt
immun
effect
complement
exploit
vaccin
design
exampl
coval
coupl
antigen
complement
factor
shown
enhanc
immunogen
given
potent
abil
activ
complement
ask
whether
coformul
antigen
gamma
inulin
might
similarli
enhanc
immunogen
test
way
gamma
inulin
prove
benefici
effect
adapt
immun
respons
mani
earli
studi
perform
keyhol
limpet
hemocyanin
klh
klh
coadminist
gamma
inulin
result
enhanc
antiklh
antibodi
respons
mice
similar
result
later
obtain
inguinea
pig
rabbit
gamma
inulin
subsequ
shown
improv
immunogen
rang
vaccin
antigen
review
mechan
adjuv
action
gamma
inulin
shown
involv
increas
deposit
surfac
macrophag
lead
enhanc
tcell
activ
although
induc
macrophag
activ
measur
chemiluminesc
respiratori
burst
gamma
inulin
prime
macrophag
greater
respiratori
burst
respons
phorbol
ester
incub
human
peripher
blood
mononuclear
cell
petrovski
tetanu
toxoid
presenc
gamma
inulin
result
enhanc
secret
compar
toxoid
alon
consist
augment
antigen
process
present
cobra
venom
deplet
serum
complement
mice
prior
immun
block
gamma
inulin
adjuv
effect
consist
adjuv
activ
depend
upon
acp
activ
attempt
enhanc
adjuv
potenc
gamma
inulin
subsequ
cocrystallis
aluminium
hydroxid
form
algammulin
prove
potent
gamma
inulin
enhanc
vaccin
antibodi
respons
nevertheless
algammulin
signific
drawback
prevent
develop
human
vaccin
adjuv
includ
ongo
concern
regard
potenti
toxic
aluminum
adjuv
potenti
issu
associ
excess
bia
high
batchtobatch
variabl
adjuv
potenc
overcom
problem
studi
undertaken
structur
function
inulin
aim
develop
stabl
consist
inulin
adjuv
platform
led
develop
delta
inulin
isoform
much
greater
consist
adjuv
activ
gamma
inulin
importantli
abl
manufactur
highli
consist
cgmp
product
delta
inulin
subsequ
form
basi
adjuv
platform
inulin
hydrophob
polyoxyethylenelik
backbon
critic
structur
solut
crystallis
inulin
particl
obtain
precipit
cold
water
refer
alpha
inulin
particl
obtain
precipit
ethanol
beta
inulin
dri
commerci
inulin
almost
alpha
beta
form
alpha
beta
isoform
highli
solubl
readili
dissolv
water
gamma
inulin
start
becom
solubl
water
delta
inulin
insolubl
temperatur
import
distinct
mean
delta
inulin
particl
insolubl
bodi
temperatur
henc
key
factor
behind
understand
delta
inulin
fact
inulin
polym
crystallis
discret
isoform
characteris
differ
solubl
rate
aqueou
media
essenc
inulin
particl
made
individu
inulin
polym
form
antiparallel
doubl
helix
helix
aggreg
togeth
later
hydrogen
bond
form
lamellar
sheet
greater
stabil
delta
inulin
compar
earlier
inulin
isoform
therebi
reflect
greater
aggreg
strength
hbond
individu
inulin
polym
form
crystal
structur
averag
length
polym
make
isoform
increas
progress
polymorph
seri
transmiss
scan
electron
microscopi
atom
forc
microscopi
studi
delta
inulin
particl
show
consist
spherulitelik
discoid
particl
micron
diamet
made
seri
lamellar
sheet
better
knowledg
structur
basi
delta
inulin
crystal
enabl
design
cgmp
product
process
therebi
ensur
abil
produc
adjuv
particl
highli
consist
size
reproduc
adjuv
properti
shown
figur
mark
contrast
highli
irregular
shape
size
inconsist
adjuv
properti
gamma
inulin
initi
delta
inulin
formul
gamma
delta
inulin
activ
complement
via
acp
known
exactli
inulin
structur
potent
complement
activ
although
high
number
surfac
hydroxyl
group
recognis
import
complement
activ
virtual
biolog
surfac
activ
acp
provid
sialic
acid
moieti
present
sialic
acid
function
discrimin
protect
vertebr
surfac
selfcompl
attack
complement
factor
moder
prefer
spontan
reaction
glucos
fructos
moieti
henc
inulin
polym
particular
featur
suggest
high
convertas
activ
activ
inde
solubl
inulin
polym
abil
activ
complement
explain
safeti
human
renal
function
test
acp
initi
lead
rapid
amplif
complement
activ
labil
convertas
product
produc
acp
activ
must
local
surfac
site
rel
protect
circul
complement
inhibitor
degrad
enzym
therefor
possibl
surfac
gamma
delta
inulin
crystal
pack
structur
relev
abil
activ
complement
despit
potent
acp
activ
capabl
gamma
delta
inulin
extrem
well
toler
even
inject
high
dose
suggest
complement
activ
induc
inulin
isoform
occur
control
fashion
avoid
excess
releas
toxic
downstream
mediat
hypothes
delta
inulin
activ
complement
regul
cluster
therebi
block
product
downstream
anaphylatoxin
complement
membran
attack
complex
could
explain
delta
inulin
abl
separ
benefici
effect
adapt
immun
upstream
complement
activ
factor
harm
downstream
effect
cell
integr
complement
membran
attack
complex
delta
inulin
multipl
advantag
adjuv
gamma
inulin
includ
greater
temperatur
stabil
abil
produc
monodispers
particl
popul
cgmp
fig
improv
adjuv
potencyin
anim
model
delta
inulin
also
resist
damag
steril
dose
gamma
irradi
gamma
inulin
highli
suscept
consequ
develop
gamma
inulin
ceas
decad
ago
effort
instead
refocuss
delta
inulin
adjuv
develop
form
adjuv
import
distinct
whilst
adjuv
compris
delta
inulin
term
delta
inulin
synonym
adjuv
also
compris
delta
inulin
highli
specif
particl
size
morpholog
therebi
distinguish
delta
inulin
gener
earli
studi
show
immun
mice
hepat
b
surfac
antigen
hbsag
plu
adjuv
provid
least
antigendos
spare
compar
standard
alumadjuv
vaccin
mice
also
show
balanc
immun
respons
contrast
extrem
seen
mice
immun
alum
adjuv
use
adjuv
ssociat
increas
tcell
prolif
respons
increas
antigenstimul
product
gmcsf
consist
broad
base
enhanc
tcell
subset
rather
strong
alum
cpg
adjuv
respect
product
increas
adjuv
suggest
unlik
alum
induc
inflammasom
activ
adjuv
effect
depend
antigen
absorpt
antibodi
respons
enhanc
even
inject
one
day
prior
antigen
advax
effect
influenza
vaccin
extens
studi
formul
inactiv
influenza
vaccin
enhanc
serum
neutral
antibodi
titer
mice
provid
antigen
spare
correl
higher
frequenc
influenzaspecif
igmand
iggsecret
b
cell
bone
marrow
spleen
immun
mice
seen
hbsag
immun
use
associ
increas
influenzaspecif
tcell
prolifer
increas
gmcsf
product
translat
enhanc
protect
lethal
influenza
challeng
immun
longliv
high
antibodi
titer
tcell
respons
influenza
protect
still
evid
year
postimmun
inject
mice
alon
absenc
antigen
provid
protect
influenza
infect
indic
induc
nonspecif
innat
immun
protect
also
shown
boost
immunogen
inactiv
influenza
vaccin
even
deliv
via
intrapulmonari
rout
adjuv
also
test
abil
help
overcom
effect
pregnancyassoci
immun
suppress
influenza
vaccin
respons
adjuv
well
toler
pregnant
dam
associ
advers
reproduct
development
effect
mother
pup
pregnant
dam
receiv
singl
intramuscular
inject
inactiv
influenza
antigen
adjuv
increas
serum
antiinfluenza
igg
titer
translat
higher
antiinfluenza
igg
titer
breast
milk
turn
result
higher
antiinfluenza
igg
titer
serum
suckl
pup
pup
complet
protect
challeng
influenza
weeksofag
contrast
surviv
seen
pup
mother
immun
standard
unadjuv
influenza
vaccin
ferret
challeng
model
adjuv
enhanc
protect
confer
licens
vaccin
highpathogen
avian
influenza
two
immun
inactiv
antigen
plu
adjuv
without
addit
cpg
oligonucleotid
induc
high
serum
neutral
antibodi
titer
wherea
antibodi
bare
detect
ferret
receiv
standard
vaccin
enhanc
surviv
reduc
clinic
diseas
absenc
brain
invas
viru
seen
group
viru
complet
clear
nasal
wash
day
postchalleng
adjuv
similarli
shown
enhanc
vaccin
protect
pulmonari
anthrax
enhanc
antibodi
respons
recombin
protect
antigen
rpa
result
enhanc
protect
lethal
anthrax
challeng
even
singl
immunis
synergist
effect
seen
murabutid
agonist
coformul
adjuv
shown
vivo
imag
cathepsin
cleavag
prosens
murabutid
induc
significantli
less
local
inject
site
inflamm
alum
adjuv
flavivirus
repres
anoth
major
vaccin
challeng
although
human
vaccin
japanes
enceph
viru
jev
current
licens
vaccin
west
nile
viru
dengu
inclus
adjuv
inactiv
jev
antigen
enhanc
neutralis
antibodi
respons
immun
mice
hors
also
associ
induct
crossneutr
antibodi
respons
murray
valley
enceph
viru
mvev
west
nile
viru
wnv
subsequ
demonstr
adjuv
enhanc
product
memori
b
cell
abl
transfer
protect
jev
relat
flavivirus
includ
mvev
mice
crossprotect
wnv
achiev
singl
dose
jev
vaccin
formul
adjuv
maintain
least
one
year
postimmun
jev
vaccin
found
safe
effect
administ
pregnant
hors
newborn
foal
similarli
induc
broadli
crossprotect
antiflaviviru
antibodi
adjuv
enhanc
neutral
antibodi
respons
protect
murin
sever
acut
respiratori
syndrom
sar
coronaviru
vaccin
model
formul
inactiv
sar
viru
recombin
spike
protein
adjuv
protect
mice
reduc
viru
titer
lung
compar
immun
either
antigen
alon
one
year
postimmun
anim
immun
vaccin
higher
sarsspecif
tcell
prolifer
respons
wherea
alumformul
sar
antigen
associ
increas
eosinophil
lung
immunopatholog
respons
challeng
sar
viru
lung
immunopatholog
absent
mice
immun
delta
inulinadjuv
vaccin
absenc
lung
immunopatholog
adjuv
group
correl
higher
frequenc
sarsspecif
cell
consist
adjuv
drive
balanc
respons
inhibit
eosinophil
lung
immunopatholog
assist
coformul
adjuv
cpg
oligonucleotid
adjuv
alon
combin
cpg
oligonucleotid
enhanc
immunogen
mice
hiv
envelop
protein
boost
follow
dna
plasmid
intramuscular
prime
therebi
induc
persist
mucos
iga
system
igg
memori
tand
bcell
respons
similarli
rabbit
nonhuman
primat
adjuv
enhanc
product
simian
immunodefici
viru
crossneutralis
antibodi
combin
envelop
protein
boost
follow
dna
vaccin
prime
adjuv
enhanc
protect
afford
listeria
vaccin
base
tcell
peptid
epitop
conjug
gold
nanoparticl
enhanc
protect
adjuv
correl
increas
frequenc
splenic
cell
nk
cell
dc
cytokin
product
associ
increas
tcell
epitop
spread
follow
live
listeria
challeng
exampl
veterinari
vaccin
adjuv
shown
benefici
effect
neutral
antibodi
respons
andor
protect
includ
vaccin
petrovski
pest
de
petit
rumin
mice
goat
african
hors
sick
meliodosi
camel
abovedescrib
preclin
studi
adjuv
administ
intramuscularli
subcutan
mimic
intend
human
use
howev
adjuv
also
effect
given
via
rout
includ
intraderm
intraperiton
intranas
deliveri
unpublish
data
recent
shown
adjuv
activ
even
administ
directli
murin
lung
intratrach
administr
dri
powder
inactiv
influenza
vaccin
togeth
adjuv
induc
higher
influenzaspecif
intranas
iga
titer
balanc
antibodi
isotyp
respons
observ
advers
effect
whilst
vast
major
immunogen
studi
adjuv
undertaken
mice
adjuv
activ
demonstr
across
broad
rang
anim
speci
includ
guinea
pig
ferret
goat
hors
camel
date
speci
limit
adjuv
action
seen
adjuv
activ
also
seen
rat
rabbit
dog
cat
sheep
unpublish
data
also
effect
across
differ
life
stage
efficaci
safe
administ
combin
inactiv
influenza
vaccin
pregnant
mice
mous
pup
combin
inactiv
japanes
enceph
vaccin
pregnant
mare
newborn
foal
adjuv
shown
work
via
danger
signal
exampl
aluminium
salt
induc
cell
necrosi
result
inflammasom
activ
also
trigger
tolllik
receptor
tlr
activ
dna
releas
lyse
cell
similarli
monophosphoryl
lipid
activ
flagellin
activ
cpg
oligonucleotid
activ
final
common
pathway
adjuv
work
via
danger
signal
activ
transcript
factor
nuclear
factorkappa
b
nfkb
master
regul
inflammatori
respons
adjuv
except
fail
induc
nfkb
activ
human
monocyt
murin
splenocyt
similarli
activ
inflammasom
induc
inflammatori
cytokin
product
unpublish
data
mechan
underli
uniqu
abil
adjuv
separ
innat
immun
activ
inflamm
enhanc
adapt
immun
subject
intens
ongo
studi
group
firstinman
phase
clinic
trial
conduct
ass
safeti
toler
three
intramuscular
dose
hbsag
formul
adjuv
healthi
adult
subject
undertaken
follow
success
preclin
acut
repeat
dose
toxicolog
studi
safeti
problem
identifi
adjuv
well
toler
trial
subject
inject
site
pain
score
significantli
differ
subject
receiv
hbsag
alon
enhanc
antihbsag
antibodi
titer
seroprotect
rate
compar
administr
hbsag
alon
proport
petrovski
subject
posit
antihbsag
tcell
respons
also
significantli
higher
subject
receiv
adjuv
phase
studi
undertaken
adult
subject
assess
abil
adjuv
enhanc
immunogen
pandem
influenza
pdm
vaccin
made
recombin
hemagglutinin
increas
seroprotect
rate
time
first
time
second
immun
compar
immun
recombin
hemagglutinin
alon
use
adjuv
toler
adjuvantassoci
advers
reaction
observ
adjuv
also
found
safe
effect
combin
bee
venombas
immunotherapi
administ
human
subject
beest
anaphylaxi
acceler
higher
titer
venomspecif
marker
success
immunotherapi
clinic
trial
advax
adjuv
success
test
includ
incombin
season
trival
inactiv
influenza
vaccin
combin
univers
tcell
vaccin
influenza
base
synthet
peptid
epitop
unpublish
data
adjuv
base
delta
inulin
microcrystallin
particl
success
enhanc
vaccin
immunogen
across
broad
rang
antigen
type
includ
whole
inactiv
virus
recombin
protein
synthet
peptid
toxin
venom
effect
across
anim
speci
test
far
activ
across
varieti
immun
rout
effect
given
pregnanc
earli
neonat
life
consist
enhanc
serum
antibodi
titer
tcell
immun
coadminist
antigen
act
synergist
tradit
innat
immun
activ
murabutid
cpg
oligonucleotid
earli
promis
preclin
studi
support
success
human
clinic
trial
confirm
safeti
toler
efficaci
ongo
prioriti
characteris
delta
inulin
mechan
action
develop
mucos
adjuv
explor
synergist
combin
immun
activ
extend
human
clinic
studi
paediatr
popul
show
inulin
compris
variablelength
chain
fructos
ring
termin
singl
glucos
ring
gener
inulin
polym
isol
plant
sourc
rang
length
fructos
unit
petrovski
vaccin
author
manuscript
avail
pmc
novemb
transmiss
electron
microscopi
tem
reveal
gamma
inulin
particl
highli
variabl
shape
size
structur
potenti
explain
larg
batchtobatch
variat
adjuv
activ
initi
delta
inulin
particl
better
defin
structur
tem
still
exhibit
consider
size
variat
b
optim
control
crystal
paramet
allow
reproduc
product
delta
inulin
particl
consist
size
shape
c
subsequ
form
basi
adjuv
freezefractur
scan
em
particl
suspend
water
reveal
discoid
petrovski
shape
format
lamellar
sheet
e
atom
forc
microscopi
particl
format
confirm
discoid
charact
also
fine
inulin
filament
precursor
final
particl
assembl
f
petrovski
vaccin
author
manuscript
avail
pmc
novemb
